Journal of Cancer 2016

5 papers
In 2016, the *Journal of Cancer* published research focused on molecular signaling hierarchies and the regulation of cell fate. A portion of the work centered on the Bcl-2 family and the protein Survivin, exploring their roles in tumorigenesis and chemosensitivity. Specific studies investigated how microRNAs like miR-34a and miR-203 modulate Survivin expression in human osteosarcoma cells, while other research examined how Nucleophosmin mutations affect NF-κB activity and the Bax/Bcl-2 ratio in leukemia cells. The year’s publications also emphasized diagnostic identification and disease modeling. Research utilized plasma metabolomics to identify biomarkers for early-stage epithelial ovarian cancer and analyzed how the subcellular localization of Pregnancy Specific β-1 Glycoprotein 1 correlates with survival in pancreatic ductal adenocarcinoma. Methodological trends included the application of CRISPR/Cas9 for isogenic disease modeling and strategies for functional rescue and neutralizing compensatory signaling. Prolific contributors during this period included researchers such as Caiguo Zhang, Wentao Zhang, and Xun Chen, who contributed to the characterization of molecular mechanisms across various malignancies.

Top Research Directions

The 9 research directions with Journal of Cancer 2016 papers, ranked by paper count, next to 2015. Share is the fraction of the edition’s papers in the direction.

#Direction20162015Share 2016Share 20152015 rank
1Inhibiting Autophagy to Overcome Chemoresistance1020.0%0.0%—
2Mapping Molecular Pathways via Epistatic Rescue Assays1120.0%25.0%8
3Measuring Transcriptional Activity with Dual Luciferase Assays1020.0%0.0%—
4Modulating the Stoichiometric Balance of Bcl-2 Family Proteins1020.0%0.0%—
5Mutual Activation Circuits in Cellular Signaling1020.0%0.0%—
6Overcoming Membrane Permeability Barriers to Intracellular Targets1020.0%0.0%—
7Resolving the Atomic Interfaces of Protein Interactions1020.0%0.0%—
8Targeting Intrinsically Disordered Proteins1020.0%0.0%—
9Therapeutic Suppression of the NF-κB and NLRP3 Pathways1020.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Cancer 2016 papers: a paper credits every institution named in its affiliations, once. 1 institutions share 1 credited papers.

#InstitutionPapersShare20152015 rank
1Chongqing Medical University 1100.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Cancer 2016 lists 5 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2015 use shares, since the edition went from 4 to 5 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 1 of 5 papers (20.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Cancer 2016”, https://lacuna.tiptreesystems.com/venue/journal-of-cancer/2016.

Top Authors

AuthorPapers
Xun Chen2

Impactful Papers

Papers from Journal of Cancer 2016 that shaped research clusters.

Influential

Papers

Title
MiR-34a and miR-203 Inhibit Survivin Expression to Control Cell Proliferation and Survival in Human Osteosarcoma Cells
Nucleophosmin Mutations Induce Chemosensitivity in THP-1 Leukemia Cells by Suppressing NF-κB Activity and Regulating Bax/Bcl-2 Expression
Pregnancy Specific β-1 Glycoprotein 1 is Expressed in Pancreatic Ductal Adenocarcinoma and its Subcellular Localization Correlates with Overall Survival
Survivin and Tumorigenesis: Molecular Mechanisms and Therapeutic Strategies
Use of Plasma Metabolomics to Identify Diagnostic Biomarkers for Early Stage Epithelial Ovarian Cancer